Ongoing Investigation into Galectin Therapeutics Inc. (GALT): Contact Levi & Korsinsky About Potential Fraud

Core Viewpoint - Galectin Therapeutics Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price after an FDA communication regarding its drug development program [1][3]. Group 1: Company Developments - On December 19, 2025, Galectin Therapeutics announced that the FDA provided a written response to its Type C meeting request concerning the development of belapectin, an investigational galectin-3 inhibitor [2]. - The FDA's response converted the company's request for an in-person or teleconference meeting into a written format, indicating that while there is alignment on the proposed patient population for a registration trial, key aspects of the trial design remain unresolved [2]. Group 2: Market Reaction - Following the FDA's communication, Galectin's stock price experienced a decline of over 28% on the same day [3].